Quanterix Corporation QTRX 深 滬
等待開盤 03-26 09:30:00 美东时间
3.96
+0.140
+3.66%
華盛通- 最 高4.127
- 今 開3.87
- 成交量 76.85万股
- 最 低 3.87
- 昨 收 3.82
- 總市值 1.86亿
- 52周最高 8.77
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 3.64
- 委 比 -83.64%
- 總股本 4694.00万
- 歷史最高 92.57
- 量 比 0.76
- 振 幅 6.73%
- 歷史最低 3.64
- 每 手 1
- 風險率 0.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quanterix targets $169M–$174M 2026 revenue with focus on diagnostics and cost synergies
Earnings Call Insights: Quanterix Corporation (QTRX) Q4 2025 Management View Everett Cunningham, President and CEO, introduced himself to investors, emphasizing his background in healthcare and commer...
03-03 17:08
Quanterix Sees FY2026 Sales $169.000M-$174.000M vs $170.835M Est
Quanterix (NASDAQ:QTRX) sees FY2026 sales of $169.000 million-$174.000 million vs $170.835 million analyst estimate.
03-03 05:24
Quanterix Earnings Report: Q4 Overview
Quanterix (NASDAQ:QTRX) announced its Q4 earnings on Monday, March 2, 2026 at 0...
03-03 05:23
Quanterix Q4 Adj. EPS $(0.47) Misses $(0.45) Estimate, Sales $43.855M Beat $38.139M Estimate
Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.45) by 4.44 percent. This is a 56.67 percent decrease over losses of $(0.30) per share from the
03-03 05:22
Quanterix Lucent Diagnostics Partners With Life Line Screening for Nationwide Blood Biomarker Testing
Quanterix Lucent Diagnostics Partners With Life Line Screening for Nationwide Blood Biomarker Testing Quanterix Corporation’s Lucent Diagnostics brand has partnered with Life Line Screening to expand access to a non-invasive blood-based biomarker test through community health events nationwide. Prog
03-02 21:33
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
Quanterix Corporation Schedules Conference Call to Discuss Fourth-Quarter and Full-Year Financial Results
Quanterix Corporation Schedules Conference Call to Discuss Fourth-Quarter and Full-Year Financial Results Quanterix Corporation will report fourth quarter and full year 2025 financial results on Monday, March 2, 2026, issuing a press release after the market closes that will be posted on http://www.
02-20 21:33
Quanterix Submits 510(k) Premarket Notification to FDA For Multi-Analyte Algorithmic Blood Test For Alzheimer's Disease
The multi-analyte test previously received Breakthrough Device Designation from the FDA, a program intended to accelerate the development and review of devices that provide for more effective treatment or diagnosis of
02-03 21:37
Quanterix Submits FDA 510(k) Application for Multi-Analyte Blood Test for Alzheimer's Detection
Quanterix Submits FDA 510(k) Application for Multi-Analyte Blood Test for Alzheimer's Detection Quanterix Corporation has announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its multi-analyte algorithmic blood test designed for Alzheimer's d
02-03 21:33
JAMA Network Open Publishes Quanterix Study Showing Multi-Biomarker Model Predicts Early Alzheimer's Progression; The Optimal Model Achieved A C-Index Of 0.90 For Identifying Individuals With SCD
Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into
01-21 21:38
